<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679549</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0011</org_study_id>
    <nct_id>NCT00679549</nct_id>
  </id_info>
  <brief_title>The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure</brief_title>
  <official_title>The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether treating sleep apnea while in the hospital would help heart
      failure, and assist recovery from the worsening of the heart function more than the current
      clinical standard of waiting for treatment until the subject have left the hospital.

      Heart failure affects more than 2% of the US population and is the only cardiovascular
      disorder with rising incidence. The annual cost of CHF in 2005 was $ 27.9 billion, large
      percentage of which is the cost of hospitalizations for exacerbation of CHF. Half of patients
      with CHF have some form of sleep apnea, and most of them go undiagnosed. Patients with CHF
      and OSA benefit from treatment with CPAP as an outpatient. The society can benefit from
      developing recommendations for approaching sleep apnea in the hospitalized CHF patient, which
      may shorten length of stay, improve functional status of discharged patient, and reduce
      rehospitalizations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target population:

      Patients admitted to the OSU Heart Hospital with ADHF routinely undergo a cardiorespiratory
      sleep study to identify OSA. Patients with ADHF who are newly diagnosed with OSA during the
      same hospital stay are eligible for this study.

      Enrollment:

      Given the presence of significant previously unrecognized OSA in 62% of patients hospitalized
      with ADHF, we expect to need to screen 270 patient volunteers to recruit 170 patients with
      OSA.

      Eligibility for randomization: The criteria for ADHF is admission diagnosis of heart failure;
      a chief complaint of dyspnea; and ejection fraction of 45% or less. Additionally, elevated
      left ventricular pressure as indicated by at least one sign and one symptom of volume
      overload (pedal edema, crackles, consistent chest X-ray, increased left ventricular
      end-diastolic diameter, or elevated BNP level) is required [46].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 22, 2014</completion_date>
  <primary_completion_date type="Actual">March 22, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>at baseline and 3 days post randomization</time_frame>
    <description>Using the modified Simpson method. LVEF is calculated as (Left ventricular end diastolic volume (LVEDV)-left ventricular end systolic volume (LVESV)/left ventricular end diastolic volume (LVEDV) *100.
the measurement unit of LVEF is %.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Heart Failure</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>DEVICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Provided CPAP as an inpatient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No device provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP Therapy</intervention_name>
    <description>CPAP therapy is provided as an inpatient.</description>
    <arm_group_label>DEVICE</arm_group_label>
    <other_name>CPAP Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously unrecognized OSA with an Apnea Hypopnea Index (AHI) &gt; 15 events per hour on
             the attended in-hospital sleep study. Patients with apnea index of less than 5 events
             / hour are excluded (see design consideration for rationale)

          -  Projected length of stay 3 days or more on the morning following the
             cardio-respiratory sleep study

          -  Ongoing or planned targeted treatment for heart failure including one of the
             following: IV diuretics, IV infusion of inotropes or vasodilators, or planned
             revascularization, or device therapy

        Exclusion Criteria:

          -  Patients who are already diagnosed with OSA

          -  Patients with Central Sleep Apnea

          -  Patients with diastolic only heart failure

          -  Cardiogenic shock and hemodynamic instability with MAP less than 55 mmHg off
             vasopressors, or concurrently on vasopressor treatment, left ventricular assist
             devices, or intra-aortic Balloon Pump. Inotropic agents will not constitute an
             exclusion criterion. Patients will be eligible once off vasopressors.

          -  Acute respiratory failure or insufficiency defined by P/F (PaO2/FIO2) ratio less than
             250, or FIO2 requirement more than 50%

          -  Overt neurological deficit

          -  Renal failure requiring renal replacement therapy; Patients will not be excluded if
             they were undergoing ultra-filtration for volume removal

          -  Patients scheduled for procedures that will interfere with post randomization
             measurement: This includes scheduled coronary bypass surgery, or expected left
             ventricular assist device placement.

          -  Patients who arrived from a long-term care facility or expected to be discharged to
             one; and patients who have very poor functional outcome precluding ability to use the
             CPAP device independently.

          -  Patients on long term or &quot;bridging&quot; inotropic infusion, or short life expectancy due
             to concomitant illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rami N Khayat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <results_first_submitted>March 11, 2019</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2019</results_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Rami Khayat</investigator_full_name>
    <investigator_title>Associate Professor-Clinical</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>OSA</keyword>
  <keyword>CHF</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>CHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>150 patients provided the baseline measurements and were randomized and included in the trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DEVICE</title>
          <description>Provided CPAP as an inpatient
CPAP Therapy: CPAP therapy is provided as an inpatient.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="66">4 dropouts in the control arm; 5 missing echocardiograms in the control arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>dropout</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing outcome echocardiograms</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DEVICE</title>
          <description>Provided CPAP as an inpatient
CPAP Therapy: CPAP therapy is provided as an inpatient.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11"/>
                    <measurement group_id="B2" value="57" spread="13.5"/>
                    <measurement group_id="B3" value="57" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Using the modified Simpson method. LVEF is calculated as (Left ventricular end diastolic volume (LVEDV)-left ventricular end systolic volume (LVESV)/left ventricular end diastolic volume (LVEDV) *100.
the measurement unit of LVEF is %.</description>
        <time_frame>at baseline and 3 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DEVICE</title>
            <description>Provided CPAP as an inpatient
CPAP Therapy: CPAP therapy is provided as an inpatient.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No device provided</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Using the modified Simpson method. LVEF is calculated as (Left ventricular end diastolic volume (LVEDV)-left ventricular end systolic volume (LVESV)/left ventricular end diastolic volume (LVEDV) *100.
the measurement unit of LVEF is %.</description>
          <units>percent ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="10.6"/>
                    <measurement group_id="O2" value="27.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conclusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="11.9"/>
                    <measurement group_id="O2" value="28.8" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months post randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DEVICE</title>
          <description>Provided CPAP as an inpatient
CPAP Therapy: CPAP therapy is provided as an inpatient.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rami Khayat</name_or_title>
      <organization>The Ohio State Unveristy</organization>
      <phone>6142477717</phone>
      <email>rami.khayat@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

